The clinical usefulness and optimal clinical dose of N-22 (Mofezolac), a new non-steroidal anti inflammatory agent, were evaluated in cases of pharyngitis, laryngitis, and tonsillitis, at two daily dosage levels of 225mg (3 times/day), and 300mg (3 times/day). A total of 81 cases (37 cases at 225mg, 44 cases at 300mg) were studied. The results are summarized as follows. Of a total of 80 cases evaluated for clinical efficacy (1 case of 81 was rejected due to sinusitis), 61.1% (22/36) of the 225mg group and 63.6% (28/44) of the 300mg group were rated “moderately improved or better” in a final global improvement rating, with no significant difference between the two groups. Symptomatic observation confirms that N-22 demonstrated an excellent analgesic effect against pharyngeal/laryngeal pain in particular. Side effects were recognized in 5 cases. One case of stomach discomfort/rough oral mucosa and 1 case of stomach discomfort alone in the 225mg group; and 1 case of heavy sensation of stomach, 1 case of drowsiness, and 1 case of diarrhea in the 300mg group were observed. None of these side effects were considered to be clinically serious, and no significant difference was found between the two groups. From this study, we found N-22 to be clinically useful with little difference between a daily dose of 225mg and 300mg. We estimate the optimal daily dose for use in pharynitis, laryngitis, and tonsillitis with pain to be 225mg.
View full abstract